Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: Susceptibility factors of multiple sclerosis?

Multiple Sclerosis

Volumn 13, Issue 4, 2007, Pages 446-453

  Sidoti, A ^a   Antognelli, C ^b   Rinaldi, C ^a   D'Angelo, R ^a   Dattola, V ^a   Girlanda, P ^a   Talesa, V ^b   Amato, Aldo ^a,c  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Division of Biology and Genetics   (Italy)

Author keywords

Glyoxalase I (GI); Lipid peroxidation; Malondialdehyde (MDA); Methylglyoxal (MG); Multiple sclerosis (MS); Neurodegenerative diseases; Paraoxonase (PON1); Polymorphisms

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARYLDIALKYLPHOSPHATASE 1; DNA; FREE RADICAL; LACTOYLGLUTATHIONE LYASE; REACTIVE OXYGEN METABOLITE;

ADULT; ARTICLE; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM; CHRONIC INFLAMMATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMYELINATION; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREDICTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCAVENGING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 34249079947     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/13524585070130040201     Document Type: Article

References (55)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-87.
2. Steinman L. Multiple sclerosis: a co-ordinated attack against myelin in the central nervous system. Cell 1996; 85: 299-302.
3. Martino G, Adorini L, Rieckmann P, Hillert J, Kallmann B, Comi G et al. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol 2002; 1: 499-509.
4. Sadovnick AD, Dircks A, Ebers GC. Genetic counselling in multiple sclerosis: risk to sibs and children of affected individuals. Clin Genet 1999; 56: 118-22.
5. Chataway J, Feakes R, Coraddu F, Gray J, Deans J, Fraser M et al. The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain 1998; 121: 1869-87.
6. Sawcer S, Maranian M, Setakis E, Curwen V, Akesson E, Hensiek A et al. A whole genome screen for linkage disequilibrium, in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain 2002; 125: 1337-47.
7. The Transatlantic Multiple Sclerosis Genetics Cooperative. A meta-analysis of genomic screens in multiple sclerosis. Mult Scler 2001; 7: 3-11.
8. Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW et al. A population-based study of multiple sclerosis in twins: update. Ann Neurol 1993; 33: 281-85.
9. Greco A, Minghetti I, Sette G, Fieschi C, Levi G. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 1999; 53: 1876-79.
10. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 2004; 251: 261-68.
11. Mickel HS. Multiple sclerosis: a new hypothesis. Perspect Biol Med 1975; 18: 363-74.
12. Lassmann H. Axonal injury in multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74: 695-97.
13. Sevanian A, Hochstein P. Mechanisms and consequences of lipid peroxidation in biological systems. Annu Rev Nutr 1985; 5: 365-90.
14. Augustin W, Wiswedel I, Noack H, Reinheckel T, Reichelt O. Role of endogenous and exogenous antioxidants in the defence against functional damage and lipid peroxidation in rat liver mitochondria. Mol Cell Biochem 1997; 174: 199-205.
15. Vladimirova O, O'Connor J, Cahill A, Alder H, Butunoi C, Kalman B. Oxidative damage to DNA in plaques of MS brains. Mult Scler 1998; 4: 413-18.
16. Lu FM, Selak M, O'Connor J, Croul S, Lorenzana C, Butunoi C et al. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J Neurol Sci 2000; 177: 95-103.
17. Vladimirova O, Lu FM, Shawver L, Kalman B. The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in controls. Inflamm Res 1999; 48: 412-16.
18. Hunter MI, Nlemadin BC, Davidson DL. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 1985; 10: 1645-52.
19. Calabrese V, Raggaele R, Cosentino E, Rizza V. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharmacol Res 1994; 14: 119-23.
20. Khula B, Luth HJ, Haferburg D, Boeck K, Arendt T, Munch G. Methylglyoxal, glyoxal, and their detoxification in Alzheimer's disease. Ann NY Acad Sci 2005; 1043: 211-16.
21. Castellani R, Smith MA, Richey PL, Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res 1996; 737: 195-200.
22. Chou SM, Wang HS, Taniguchi A, Bucala R. Advanced glycation endproducts in neurofilament conglomeration of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Mol Med 1998; 4: 324-32.
23. Thornalley PJ. Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interact 1998; 111: 137-51.
24. Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T et al. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol 2000; 59: 1094-105.
25. Thornalley PJ. Glyoxalase I-structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003; 31: 1343-48.
26. Thornalley PJ. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990; 269: 1-11.
27. Agadjanyan ZS, Dmitriev LF, Dugin SF. A new role of phosphoglucose isomerase. Involvement of the glycolytic enzyme in aldheyde metabolism. Biochem J 2005; (in press).
28. Munch G, Schicktanz D, Behme A, Gerlach M, Riederer P, Palm D et al. Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat Biotechnol 1999; 17: 1006-10.
29. Amicarelli F, Colafarina S, Cattani F, Cimini A, Di Ilio C, Ceru MP et al. Scavenging system efficiency is crucial for cell resistance to ROS-mediated methylglyoxal injury. Free Radic Biol Med 2003; 35: 856-71.
30. Du J, Suzuki H, Nagase F, Akhand AA, Ma X, Yokoyama T et al. Superoxide-mediated early oxidation and activation of ASK1 are important for initiating methylglyoxal-induced apoptosis process. Free Radic Biol Med 2001; 31: 469-78.
31. Liu BF, Miyata S, Hirota Y, Higo S, Miyazaki H, Fukunaga M et al. Methylglyoxal induces apoptosis through activation of p38 mitogen-activated protein kinase in rat mesangial cells. Kidney Int 2003; 63: 947-57.
32. Shukla VKS, Jensen GE, Clausen J. Erythrocyte glutathione peroxidase deficiency in multiple sclerosis. Acta Neurol Scand 1977; 56: 542-50.
33. Jensen GE, Clausen J. Glutathione peroxidase and reductase, glucose-6-phosphate dehydrogenase and catalase activities in multiple sclerosis. J Neurol Sci 1984; 63: 45-53.
34. Junaid MA, Kowal D, Barua M, Pullarkat PS, Brooks SS, Pullarkat RK. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet 2004; 131: 11-17.
35. Newcombe J, Li H, Cuzner ML. Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis. Neuropathol Appl Neurobiol 1994; 20: 152-62.
36. Keller JN, Hanni KB, Kindy MS. Oxidized high density lipoprotein induces neuron death. Exp Neurol 2000; 161: 621-30.
37. Bassett CN, Montine KS, Neely MD, Swift LL, Montine TJ. Cerebrospinal fluid lipoproteins in Alzheimer's disease. Microsc Res Tech 2000; 5O: 282-86.
38. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U et al. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 2000; 28: 351-60.
39. La Du BN. Human serum paraoxonase/arylesterase. In Kalow W ed. Pharmacogenetics of drugs metabolism. Pergamon Press, 1992: 51-91.
40. Mackness B, Durrington PN, Mackness MI. The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 2002; 13: 357-62.
41. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
42. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81: 766-79.
43. Jaouad L, Milochevitch C, Khalil A. PON1 paraoxonase activity is reduced during HD1 oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res 2003; 37: 77-83.
44. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola. G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004; 89: 2957-62.
45. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38: 163-69.
46. Traverso, N, Menini S, Maineri EP, Patriarca S, Odetti P, Cottalasso, D et al. Malondialdehyde, a lipoperoxidation-derived aldehyde, can bring about secondary oxidative damage to proteins. Gerontol A Biol Sci Med Sci 2004; 59: B890-95.
47. Humbert R, Alder DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-76.
48. Akhmedova SN, Yakimovsky AR, Schwartz EI. Paraoxonase 1 Met-Leu54 polymorphism is associated with Parkinson's disease. J Neurol Sci 2001; 184: 179-82.
49. Zintzaras E, Hadjigeorgiou GM. York Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease. J Hum Genet 2004; 49: 474-81.
50. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
51. Tafti M, Petit B, Chollet D, Neidhart E, de Bilbao F, Kiss JZ et al. Deficiency in short-chain fatty acid betaoxidation affects theta oscillation during sleep. Nat Genet 2003; 34: 320-25.
52. Stafforini, DM, Kushner JP, Burnham BF. The effect of glyoxalase I on the metabolism of 4,5-dioxovaleric acid. Biochim Biophys Acta 1985; 839: 191-98.
53. Gardemann A, Philipp M, Heb K, Katz N, Tillmanns H, Haberbosch W. The paraoxonase Leu-Met54 and Gln-Argl9l gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 2000; 152: 421-31.
54. Ferrè N, Camps J, Fernandez-Ballart J, Arija V, Murphy MH, Cerveco S et al. Regulation of serum paraoxonase activity by genetic, nutritional and life style factors in the general population. Clin Chem 2003; 49: 1491-97.
55. Sidoti A, Robledo, R, Rinaldi A, D'Angelo R, Rinaldi C, Amato A. Further data on a 9.1 kb insertion/deletion polymorphism: a survey on mediterranean populations. Hum Biol (in press).